A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

Janssen (J&J Innovative Medicine)

Status and phase: Enrolling; Phase 4

Conditions: Depressive Disorder, Treatment-Resistant

Treatments: Drug: Esketamine 56 mg; Drug: Esketamine 84 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT07053345

54135419TRD4017 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).

Enrollment: 47 estimated patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have a confirmed diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the time of enrollment, without psychotic features, based on clinical assessment, and confirmed by mini international neuropsychiatric interview (MINI)
• Must have a Hamilton depression rating scale (HAM-D; 17-item) total score greater than or equal to (>=) 22 at screening and Day 1
• Participants must have had non-response (less than or equal to [<=] 25 percent [%] improvement of symptoms) to >= 2 oral antidepressant treatments in the current moderate to severe episode of depression after having been given at an adequate dosage for an adequate duration of at least 6 weeks
• At baseline (Day 1), the investigator will evaluate any changes in the participant's signs/symptoms of depression since the screening assessment and confirm that the inclusion criteria for the current antidepressant (AD) treatment are still met (that is, nonresponse and minimal clinical improvement)
• A female participant of childbearing potential must have a negative serum pregnancy test at screening and urine prior to the first dose of study intervention on Day 1

Exclusion criteria

• Participants with hyperthyroidism that has not been sufficiently treated
• History of malignancy within 5 years of enrollment before screening
• Known allergies, hypersensitivity, or intolerance to esketamine/ketamine or its excipients
• Received an investigational intervention or used an invasive investigational medical device within 60 days before the planned first dose of study intervention or first data collection time point
• Currently enrolled in an investigational study that involves treatments for MDD or may otherwise be expected to impact mood

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

47 participants in 1 patient group

Esketamine Nasal Spray

Experimental group

Description:

Participants will self-administer one esketamine (flexibly dosed; 56 or 84 milligrams \[mg\]) nasal spray into each nostril (that is, a total of 2 sprays using 1 intranasal device) twice a week for 4 weeks. For 84 mg, sprays to each nostril will be delivered in rapid succession at 3 different time points (3 devices total). 56 mg will have 2 devices.

Treatment:

Drug: Esketamine 84 mg

Drug: Esketamine 56 mg